Thanks, Ebrahim, it's a great question. I think we've benefited significantly already by being patient, obviously, as valuations change. And I think to your point, we're trying to present a balanced view of the economy right now and that we're mid-cycle, but many late cycle signals to your point. And as central banks struggle to contain inflation, they have to hit demand really hard, and therefore, it's difficult to predict from a macro perspective the impact of rates on demand combined with the impact of inflation on demand and lack of services to meet that demand. So I think from that perspective, markets are struggling to predict how we land the economy, do we land it with a slight recession. And our message today is, it could go either way, it's 50-50. Having said that, there are strong underlying tenants to the economies of liquidity or kind of full of employment and therefore, there are good shock absorbers to absorb that uncertainty. However, the central banks will hit demand pretty hard, and we're forecasting demand -- or GDP next year to be roughly 2% in Canada. So as you think about that trajectory in line with being opportunistic, I think to your point, patients has been rewarded, and therefore, do you really want to pick up someone else's credible at this point in time? Or do you want to see how this plays out a little bit further? So from that perspective, we remain in a balanced posture, which you heard us comment on all our speeches around RWA growth, around share buybacks and around dividends. So I think from that perspective, continue to see us focus on creating, we think, premium shareholder value, shareholder TSR through those 3 balanced mechanisms. I think you'll expect that as our first strategy right now. And then always -- look, because we have such significant organic capital bill because of, as you referenced, the upcoming regulatory changes, we still have significant excess capital to be opportunistic and therefore, we think patients will be rewarded.